AMGN|Analyst Targets
AMGN|Company Info
AMGN|Insider Trading
AMGN|Fundamentals
AMGN|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $5.76 | - | - |
| Q2'26 | $5.73 | $6.29 | +9.8% |
| Q1'26 | $4.77 | $5.15 | +8.0% |
| Q4'25 | $4.83 | $5.29 | +9.6% |
| Q3'25 | $5.01 | $5.64 | +12.5% |
| Q2'25 | $5.28 | $6.02 | +14.1% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $10.2B | - | - |
| Q2'26 | $9.6B | $10.1B | +4.6% |
| Q1'26 | $8.6B | $8.6B | +0.5% |
| Q4'25 | $9.7B | $9.9B | +2.1% |
| Q3'25 | - | $9.6B | - |
| Q2'25 | - | $9.2B | - |
AMGN|Monthly Returns
Market Data
AMGN Stock Snapshot
- Market cap
- 224.29B
- P/E ratio
- 25.6
- Day range
- $411.04 – $421.97
- News sentiment
- 54/100 · Neutral
- Analyst target
- $393.91 (-4.6%)
- Consensus
- Hold · 43 analysts
Amgen Inc. is consolidating: price is in the upper part of its 52-week range without a decisive push either way. A stock this widely held moves on consensus revisions more than on individual catalysts.
Reverse DCF
What growth is priced into AMGN?
At today's price, Amgen Inc. needs to grow free cash flow about 14.1% a year for the next 10 years to justify its valuation at a 7.55% cost of capital. Over its actual history it has compounded free cash flow at 4.3% a year, so the market is asking for 9.8 percentage points above its own delivered rate. On that basis AMGN looks priced above what its own growth record supports.
- Implied FCF growth
- 14.1%
- Historical FCF CAGR
- 4.3%
- Growth gap
- +9.8 pts
- Verdict
- RICH
- Discount rate (WACC)
- 7.55%
- Beta
- 0.62
Behaviour On Record
What AMGN's own history says about today's numbers
- Realized volatility (21d)
- 27.7% 74th pct
- Below its peak
- -6.6%
- vs 200-day average
- +13.4%
- Up days (1y)
- 52%
Amgen Inc. is currently running 27.7% annualised volatility over the last 21 sessions. Measured against AMGN's own 13 years of daily returns rather than a market-wide average, that is the 74th percentile — a little above its own norm, against a typical reading of 22.0%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
AMGN is trading -6.6% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -21.4%, and the deepest was -26.3% in 2020. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +13.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 88th percentile — a wider gap than this stock usually carries. Over the past year AMGN closed higher on 52% of sessions, and it is currently 1 session into a rising streak.
On October specifically: over 13 years of records, AMGN finished the month higher 5 of 13 times, with a median return of -0.7% and an average of +0.8%. Its strongest month historically has been July at +3.9% on average, its weakest September at -1.3%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: AMGN has opened more than 2% away from the prior close in 44 of 3,264 sessions (1.3% of the time), with the largest gaps running +5.4% and -9.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, AMGN moved an average of 5.2% in the session after earnings, closing higher 2 of those 3 times, with a median move of +4.9% and a largest of +6.9%.
All figures computed from 3,265 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against AMGN's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of AMGN's sector?
Amgen Inc. sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving).
- Sector rank
- #4 of 12
- Sector state
- Improving
- Sector rotation score
- 73
Analyst Rating Changes
Are analysts turning bullish or bearish on AMGN?
Guggenheim most recently reiterated its rating on Amgen Inc. to Neutral on Oct 13, 2026 with a price target of $378 (from $388). Over the last 90 days, coverage has run 0 upgrades against 2 downgrades, a net bearish lean.
- Latest action
- Guggenheim — Neutral
- 90-day upgrades
- 0
- 90-day downgrades
- 2
- Net rating momentum
- -2
Peers & ETF holders
AMGN peers & ETF holders
Drug Manufacturers - GeneralMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▲ Buy | 54,838,826 | 10.09% | $17.95B | 2026-01-29 |
| BlackRock, Inc. | ▲ Buy | 49,362,016 | 9.09% | $17.87B | 2026-08-07 |
| Capital World Investors | ▼ Sell | 29,075,329 | 5.35% | $10.53B | 2026-08-12 |
| Invesco Ltd. | ▲ Buy | 16,320,446 | 3.00% | $5.91B | 2026-08-14 |
| Geode Capital Management, LLC | ▲ Buy | 15,696,068 | 2.89% | $5.67B | 2026-08-12 |
| Morgan Stanley | ▼ Sell | 13,653,692 | 2.51% | $4.94B | 2026-08-13 |
| Wells Fargo & Company | ▲ Buy | 7,235,462 | 1.33% | $2.62B | 2026-08-14 |
| Capital Research Global Investors | ▼ Sell | 6,272,625 | 1.15% | $2.27B | 2026-08-12 |
| Northern Trust Corp | ▼ Sell | 6,200,994 | 1.14% | $2.25B | 2026-08-13 |
| Norges Bank | ▼ Sell | 5,625,584 | 1.04% | $2.04B | 2026-08-12 |
| Bank of America Corp | ▼ Sell | 5,058,830 | 0.93% | $1.83B | 2026-08-14 |
| Goldman Sachs Group Inc | ▼ Sell | 4,130,732 | 0.76% | $1.50B | 2026-08-14 |
| JPMorgan Chase & Co | ▼ Sell | 3,588,484 | 0.66% | $1.29B | 2026-08-12 |
| FMR LLC (Fidelity) | ▼ Sell | 3,491,822 | 0.64% | $1.26B | 2026-08-13 |
| Wellington Management Group LLP | ▲ Buy | 2,742,271 | 0.50% | $993.03M | 2026-08-14 |
| Fisher Asset Management, LLC | ▲ Buy | 1,589,554 | 0.29% | $575.61M | 2026-08-04 |
| D. E. Shaw & Co., Inc. | ▲ Buy | 1,290,217 | 0.24% | $467.21M | 2026-08-14 |
| Two Sigma Investments, LP | ▲ Buy | 1,128,681 | 0.21% | $408.72M | 2026-08-14 |
| Janus Henderson Group plc | ▼ Sell | 1,107,159 | 0.20% | $389.51M | 2026-05-18 |
| Citigroup Inc | ▲ Buy | 1,020,869 | 0.19% | $369.68M | 2026-08-03 |
| Citadel Advisors LLC | ▲ Buy | 703,984 | 0.13% | $254.93M | 2026-09-02 |
| Neuberger Berman Group LLC | ▲ Buy | 646,798 | 0.12% | $234.17M | 2026-08-13 |
| Prudential Financial Inc | ▲ Buy | 578,474 | 0.11% | $209.48M | 2026-08-12 |
| AllianceBernstein L.P. | ▼ Sell | 587,270 | 0.11% | $206.63M | 2026-08-14 |
| Adage Capital Partners GP, L.L.C. | ▲ Buy | 471,833 | 0.09% | $170.86M | 2026-08-14 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| David J. Taylor | House | OH02 | ▲ Buy | $1K - $15K | 2026-09-22 | 2026-10-01 |
| David J. Taylor | House | OH02 | ▼ Sell | $1K - $15K | 2026-08-26 | 2026-09-05 |
| Sheldon Whitehouse | Senate | RI | ▼ Sell | $1K - $15K | 2026-08-12 | 2026-09-02 |
| David J. Taylor | House | OH02 | ▲ Buy | $1K - $15K | 2026-06-05 | 2026-06-12 |
| Maria Elvira Salazar | House | FL27 | ▼ Sell | $15K - $50K | 2026-04-17 | 2026-05-08 |
| Alan Armstrong | Senate | OK | ▼ Sell | $15K - $50K | 2026-03-27 | 2026-07-21 |
| Maria Elvira Salazar | House | FL27 | ▲ Buy | $15K - $50K | 2026-03-24 | 2026-04-21 |
| David J. Taylor | House | OH02 | ▼ Sell | $1K - $15K | 2026-02-26 | 2026-03-06 |
| David J. Taylor | House | OH02 | ▼ Sell | $1K - $15K | 2026-01-29 | 2026-02-02 |
| David J. Taylor | House | OH02 | ▲ Buy | $1K - $15K | 2026-01-16 | 2026-02-02 |
| David J. Taylor | House | OH02 | ▼ Sell | $1K - $15K | 2025-12-03 | 2025-12-05 |
| Marjorie Taylor Greene | House | GA14 | ▲ Buy | $1K - $15K | 2025-10-24 | 2025-10-28 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-09-25 | 2025-10-22 |
| Marjorie Taylor Greene | House | GA14 | ▲ Buy | $1K - $15K | 2025-09-11 | 2025-09-27 |
| Sheldon Whitehouse | Senate | RI | ▼ Sell | $1K - $15K | 2025-09-04 | 2025-10-03 |
| Lisa McClain | House | MI09 | ▲ Buy | $1K - $15K | 2025-06-24 | 2025-08-13 |
| Cliff Bentz | House | OR02 | ▲ Buy | $1K - $15K | 2025-06-06 | 2025-07-09 |
| Marjorie Taylor Greene | House | GA14 | ▲ Buy | $1K - $15K | 2025-05-14 | 2025-05-19 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $15K - $50K | 2025-05-12 | 2025-06-22 |
| Marjorie Taylor Greene | House | GA14 | ▲ Buy | $1K - $15K | 2025-05-05 | 2025-05-06 |
| Jared Moskowitz | House | FL23 | ▲ Buy | $1K - $15K | 2025-04-16 | 2025-05-09 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $15K - $50K | 2025-04-15 | 2026-08-05 |
| Jefferson Shreve | House | IN06 | ▲ Buy | $15K - $50K | 2025-04-11 | 2025-05-08 |
| Rob Bresnahan | House | PA08 | ▼ Sell | $1K - $15K | 2025-04-08 | 2025-05-08 |
| Jefferson Shreve | House | IN06 | ▲ Buy | $15K - $50K | 2025-02-24 | 2025-03-09 |